Maricann Group has announced the appointment of Scott Langille as the Company's Chief Financial Officer, subject to regulatory approval.
Scott has over 30 years of experience in the pharmaceutical industry in both Canada and the United States. He was formerly Chief Financial Officer of Tribute Pharmaceuticals Canada, which was sold to Pozen Inc in February 2016 for US$160 million to form Aralez Pharmaceuticals. Scott Langille also served as Chief Financial Officer of Virexx Medical Corp., a biotechnology company, Director, Corporate Finance at Biovail Corporation, Director of Finance at Biovail Pharmaceuticals Canada, Biovail's sales and marketing division in Canada, as well as Vice President at Biovail Pharmaceuticals Inc, Biovail's sales and marketing division in the United States. Other prior management positions include Director, Finance at AltiMed Pharmaceuticals Company and Controller at Zimmer Canada.
"We are delighted to have Scott Langille join Maricann in the capacity of CFO. Scott's extensive experience in strategic planning, business development, corporate financing and strong financial oversight make him a welcome member of the executive team, as we move forward with Maricann's global initiatives," said Ben Ward, CEO of Maricann.
